Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

MK-677 vs GHRP-6

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

MK-677 has stronger documented evidence (Phase 3 (not approved)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

MK-677

Phase 3 (not approved)

GHRP-6

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: water retention. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

MK-677 GHRP-6
Class Oral non-peptide ghrelin receptor agonist GHRP; ghrelin receptor agonist
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine GHS-R1a agonist with strong orexigenic effect
Route Oral SC / Intranasal
Half-life ~24 hrs ~15-30 min
Dosage (research) 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) 100-300 mcg SC 2-3x daily
Evidence tier Phase 3 (not approved) Anecdotal + Animal Studies
Research depth 120 indexed (PubMed 97 · CT 8 · EPMC 15) 163 indexed (PubMed 141 · CT 0 · EPMC 22)
Availability Research Chemical Research Chemical
Reported risks Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) Strong hunger; cortisol/prolactin rise; water retention

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick MK-677 or GHRP-6?

MK-677 has stronger documented evidence (Phase 3 (not approved)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between MK-677 and GHRP-6?

MK-677 is classed as Oral non-peptide ghrelin receptor agonist; GHRP-6 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; GHRP-6, GHS-R1a agonist with strong orexigenic effect. Reported half-life: MK-677, ~24 hrs; GHRP-6, ~15-30 min. Routes in published studies: MK-677, Oral; GHRP-6, SC / Intranasal.

Which has stronger evidence, MK-677 or GHRP-6?

MK-677 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies.

Which is more accessible, MK-677 or GHRP-6?

Neither MK-677 nor GHRP-6 is an FDA-approved drug. Catalog status: MK-677, Research Chemical; GHRP-6, Research Chemical. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022). FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are MK-677 and GHRP-6 ever combined?

MK-677 and GHRP-6 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…